Literature DB >> 16325770

Glycated albumin and cross-linking of CD44 induce scavenger receptor expression and uptake of oxidized LDL in human monocytes.

Hirofumi Kishikawa1, Shinichiro Mine, Chie Kawahara, Takahiro Tabata, Akiko Hirose, Yosuke Okada, Yoshiya Tanaka.   

Abstract

Functional role of CD44, a principal receptor of hyaluronan, and glycated albumin for differentiation of resting human monocytes isolated by counterflow centrifugal elutriation was investigated. Flow cytometric analysis revealed that amadori-modified glycated albumin induced expression of CD44 as well as macrophage scavenger receptors (MSRs) such as CD36 and CD68 on resting monocytes. Crosslinking of CD44 on monocytes also induced MSR expression. Furthermore, CD44 crosslinking and/or glycated albumin enhanced the uptake of oxidized-low density lipoprotein in monocytes and foam cell formation. Taken together, engagement of CD44 (e.g., hyaluronan) and glycated albumin induced the differentiation of resting monocytes into foam macrophages through the induction of MSRs, implying that CD44 could be involved in atherosclerotic lesions of those such as diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325770     DOI: 10.1016/j.bbrc.2005.11.091

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  The CD44-HA axis and inflammation in atherosclerosis: A temporal perspective.

Authors:  Mia Krolikoski; James Monslow; Ellen Puré
Journal:  Matrix Biol       Date:  2018-05-21       Impact factor: 11.583

2.  MiR-199a-3p Restrains Foaming and Inflammation by Regulating RUNX1 in Macrophages.

Authors:  Mingxin Liu; Yiming Cao; Yu Hu; Zhe Zhang; Sitong Ji; Linyang Shi; Guizhou Tao
Journal:  Mol Biotechnol       Date:  2022-04-18       Impact factor: 2.860

Review 3.  Macrophage-Based Therapies for Atherosclerosis Management.

Authors:  Renyi Peng; Hao Ji; Libo Jin; Sue Lin; Yijiang Huang; Ke Xu; Qinsi Yang; Da Sun; Wei Wu
Journal:  J Immunol Res       Date:  2020-01-29       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.